12418935

Source:http://linkedlifedata.com/resource/pubmed/id/12418935

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0020473, umls-concept:C0030705, umls-concept:C0031809, umls-concept:C0035647, umls-concept:C0073393, umls-concept:C0085862, umls-concept:C0171023, umls-concept:C0332157, umls-concept:C1280500, umls-concept:C1299583, umls-concept:C1549571, umls-concept:C1608386
pubmed:issue	11
pubmed:dateCreated	2002-11-6
pubmed:abstractText	The newer antipsychotic agents exhibit a superior safety profile compared with conventional antipsychotic agents in terms of extrapyramidal symptoms. Previous studies have suggested an association between olanzapine treatment and hyperlipidemia. We evaluated this association using a large health care database.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372435
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepines, http://linkedlifedata.com/resource/pubmed/chemical/Pirenzepine, http://linkedlifedata.com/resource/pubmed/chemical/Risperidone, http://linkedlifedata.com/resource/pubmed/chemical/olanzapine
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0003-990X
pubmed:author	pubmed-author:BuchananRobert WRW, pubmed-author:FedderDonald ODO, pubmed-author:KoroCarol ECE, pubmed-author:KreyenbuhlJulieJ, pubmed-author:L'ItalienGilbert JGJ, pubmed-author:MagderLaurence SLS, pubmed-author:RevickiDennisD, pubmed-author:WeissSheilaS
pubmed:issnType	Print
pubmed:volume	59
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1021-6
pubmed:dateRevised	2008-11-21
pubmed:meshHeading	pubmed-meshheading:12418935-Adult, pubmed-meshheading:12418935-Adverse Drug Reaction Reporting Systems, pubmed-meshheading:12418935-Aged, pubmed-meshheading:12418935-Antipsychotic Agents, pubmed-meshheading:12418935-Benzodiazepines, pubmed-meshheading:12418935-Case-Control Studies, pubmed-meshheading:12418935-England, pubmed-meshheading:12418935-Female, pubmed-meshheading:12418935-Humans, pubmed-meshheading:12418935-Hyperlipidemias, pubmed-meshheading:12418935-Male, pubmed-meshheading:12418935-Middle Aged, pubmed-meshheading:12418935-Odds Ratio, pubmed-meshheading:12418935-Pirenzepine, pubmed-meshheading:12418935-Product Surveillance, Postmarketing, pubmed-meshheading:12418935-Risperidone, pubmed-meshheading:12418935-Schizophrenia, pubmed-meshheading:12418935-Schizophrenic Psychology, pubmed-meshheading:12418935-Wales
pubmed:year	2002
pubmed:articleTitle	An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
pubmed:affiliation	School of Pharmacy, University of Maryland, 506 W Fayette St, Suite 201, Baltimore, MD 21201, USA. ckoro001@umaryland.edu
pubmed:publicationType	Journal Article, Comparative Study, Evaluation Studies